Oncotarget · 2016 · 57 citations · 21 references
MedicineMolecular BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCancer ProgressionHer2-positive Breast CancerOncogenic Signaling PathwaysSignal Transduction In CancerBreast Cancer PrognosisBreast Cancer ProgressionCell InvasionCell Motility ModulationHer2 ExpressionHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionTumor Cell MotilityTumor Growth Dynamics
// Myeongjin Jeon 1, 2 , Daeun You 1, 2 , Soo Youn Bae 1 , Seok Won Kim 1 , Seok Jin Nam 1 , Hyeon Ho Kim 2 , Sangmin Kim 1 and Jeong Eon Lee 1, 2 1 Department of Surgery, Samsung Medical Center, Gangnam-gu, Seoul 06351, Korea 2 Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Gangnam-gu, Seoul 06351, Korea Correspondence to: Sangmin Kim, email: sangmin3005.kim@samsung.com Jeong Eon Lee, email: paojlus@hanmail.net Keywords: ACTA2, HER2, STAT1, invasion, metastasis Received: April 14, 2016 Accepted: July 10, 2016 Published: July 26, 2016 ABSTRACT The dimerization of EGFR and HER2 is associated with poor prognosis such as induction of tumor growth and cell invasion compared to when EGFR remains as a homodimer. However, the mechanism for events after dimerization in breast cancer models is not clear. We found that expressions of alpha-smooth muscle actin (ACTA2) and signal transducer and activator of transcription 1 (STAT1) significantly increased with transient or stable overexpression of HER2 in EGFR-positive breast cancer cells. ACTA2 and STAT1 expression was also increased in HER2-positive breast cancer patients. In contrast, ACTA2 expression was decreased by HER2 siRNA. Next, we investigated the co-relation between STAT1 and ACTA2 expression. Basal ACTA2 expression was significantly decreased by treatment with the STAT1 inhibitor fludarabine or the JAK2 inhibitor AG490. In contrast, ACTA2 expression was increased by STAT1 overexpression. Levels of ACTA2, STAT1, and HER2 were increased and relapse free survival was decreased in high-risk breast cancer patients. We also investigated the effect of ACTA2 on cell motility, which was suppressed by ACTA2 shRNA overexpression in MDA-MB231 HER2 and 4T1 mammary carcinoma cells. The number of lung metastatic nodules was significantly decreased in ACTA2 knockdown mice. Taken together, these results demonstrated that induction of ACTA2 by EGFR and HER2 dimerization was regulated through a JAK2/STAT1 signaling pathway, and aberrant ACTA2 expression accelerated the invasiveness and metastasis of breast cancer cells.
21
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Metastatic Behavior of Breast Cancer Subtypes
Hagen F. Kennecke, Rinat Yerushalmi, Ryan Woods et al. · Journal of Clinical Oncology · 2010 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +14
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Alan L. Schechter, David F. Stern, Lalitha Vaidyanathan et al. · Nature · 1984 · 1.2K citations